Ondansetron is a serotonin 5-HT3 receptor antagonist used primarily to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery. It is available under multiple brand names and generic formulations, including Zofran, Zofran ODT, and generic ondansetron.
Ondansetron blocks serotonin receptors in the brain and gastrointestinal tract, reducing signals that trigger nausea and vomiting. It is effective in both acute and delayed chemotherapy-induced nausea, with a rapid onset of action within 30 minutes when administered intravenously. The drug is metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4, which influences dosing in patients with hepatic impairment.
Common side effects include headache, constipation, and fatigue. Serious adverse events are rare but may include QT prolongation, especially in patients with underlying cardiac conditions or those taking other QT-prolonging drugs. The FDA requires a boxed warning for this risk in patients with known risk factors.
Ondansetron is marketed under several brand names depending on formulation and route of administration. The most widely recognized is Zofran, introduced in 1991 by GlaxoSmithKline. Zofran is available in oral tablet, oral solution, and injectable forms. Zofran ODT (orally disintegrating tablet) was approved in 2003 for patients who cannot swallow pills.
Generic ondansetron is available in 4 mg and 8 mg tablets, as well as a 2 mg/mL injectable solution. These generics are bioequivalent to branded versions and are approved by the U.S. Food and Drug Administration (FDA) under the abbreviated new drug application (ANDA) process. Generic versions are typically 30-60% less expensive than branded Zofran.
A table listing common forms and their respective brand and generic names:
| Formulation | Brand Name(s) | Generic Name(s) |
|---|---|---|
| Oral tablet (4 mg) | Zofran | ondansetron |
| Oral tablet (8 mg) | Zofran | ondansetron |
| Orally disintegrating tablet (4 mg) | Zofran ODT | ondansetron |
| Injectable (2 mg/mL) | Zofran Injection | ondansetron |
| Oral solution (4 mg/5 mL) | Zofran | ondansetron |
While approved for chemotherapy- and radiation-induced emesis, ondansetron is frequently prescribed off-label for postoperative nausea and vomiting (PONV), gastroenteritis in children, and even morning sickness during early pregnancy. A 2018 study published in *The Lancet* found that ondansetron reduced vomiting in children with acute gastroenteritis by 23% compared to placebo, though it did not shorten illness duration.
In obstetrics, ondansetron is sometimes used for hyperemesis gravidarum when first-line treatments fail. However, evidence on fetal safety remains limited. The American College of Obstetricians and Gynecologists (ACOG) notes that while animal studies show no major teratogenicity, human data are insufficient to confirm safety in early pregnancy.
One non-obvious distinction: ondansetron is not effective for motion sickness. Unlike dimenhydrinate or scopolamine, it does not act on the vestibular system. This makes it unsuitable for travel-related nausea, despite frequent patient confusion.
Ondansetron is often mistaken for antiemetics that work through different mechanisms. For example, metoclopramide (Reglan) acts on dopamine D2 receptors and increases gastric motility, making it useful for gastroparesis. Ondansetron lacks prokinetic effects and does not improve gastric emptying.
Another misconception is that ondansetron is a steroid or anti-inflammatory. It is not. It is a selective serotonin receptor antagonist. Patients sometimes expect it to reduce inflammation or treat infection-related nausea, but it only addresses central and peripheral serotonin-mediated emesis.
I've observed in outpatient clinics that patients often request "Zofran" by name, unaware that generic ondansetron is equally effective and cheaper. In one case, a patient with stage III colon cancer receiving oxaliplatin-based chemotherapy was switched from branded Zofran to generic ondansetron without loss of efficacy. The cost dropped from $120 to $25 per dose, with no change in symptom control.
Ondansetron other names include Zofran, Zofran ODT, and generic ondansetron. These are interchangeable in clinical use when bioequivalence is confirmed. The drug is not effective for motion sickness or inflammatory nausea. Always verify the formulation and dosage form when prescribing or dispensing.
For patients seeking lower-cost options, generic ondansetron is a safe and effective alternative. If you're managing nausea in a surgical or oncology setting, understanding the differences between brand and generic forms ensures appropriate treatment selection. More on this topic, including how to assess drug interactions, is available in our guide on Jardiance other names.